Please assess the completion status of the following clinical trial:

Trial Title: Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female or male subjects with T1DM for at least 1 year; diagnostic criteria as defined by the American Diabetes Association (3).~* Treated with insulin for T1DM for at least 1 year and with stable insulin treatment (defined as no more than a 10-unit daily variation in total daily insulin dose) 30 days prior to screening~* Hemoglobin A1c \<10%.~* Aged between 18 and 75 years, both inclusive.~Exclusion Criteria:~* Previous participation in a clinical trial within the dasiglucagon in the rescue treatment of hypoglycemia program.~* Known or suspected allergy to trial drug(s) or related products.~* History of anaphylaxis or symptoms of severe systemic allergy (such as angioedema).~* Previous participation in this trial. Participation being defined by signing the informed consent document.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Dasiglucagon (Type: EXPERIMENTAL): single fixed dose (subcutaneous injection) of dasiglucagon
- Placebo (Type: PLACEBO_COMPARATOR): single fixed dose (subcutaneous injection) of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).